|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6287590B1
(en)
|
1997-10-02 |
2001-09-11 |
Esperion Therapeutics, Inc. |
Peptide/lipid complex formation by co-lyophilization
|
|
MXPA01009893A
(es)
|
1999-04-01 |
2003-07-28 |
Esperion Therapeutics Inc |
Compuestos con eter, composiciones y usos de estos.
|
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
US7407662B2
(en)
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
|
US7439052B2
(en)
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
|
US7407663B2
(en)
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
|
US20090017069A1
(en)
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
EP2343317A1
(en)
*
|
2000-11-10 |
2011-07-13 |
F. Hoffmann-La Roche Ltd. |
Apolipoprotein analogues
|
|
KR101172045B1
(ko)
|
2000-11-10 |
2013-05-14 |
에프. 호프만-라 로슈 리미티드 |
아포리포단백질 유사체
|
|
US20060060520A1
(en)
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
WO2003000381A1
(en)
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US6991727B2
(en)
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
AU2002362612B2
(en)
*
|
2001-09-28 |
2007-11-15 |
Cedars-Sinai Medical Center |
Prevention and treatment of restenosis by local administration of drug
|
|
JP2005518266A
(ja)
*
|
2001-09-28 |
2005-06-23 |
エスペリオン セラピューティクス，インコーポレイテッド |
高圧でベシクルを押し出す方法および装置
|
|
US7470659B2
(en)
|
2001-12-07 |
2008-12-30 |
The Regents Of The University Of California |
Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
|
|
US20030229062A1
(en)
*
|
2001-12-07 |
2003-12-11 |
The Regents Of The University Of California |
Treatments for age-related macular degeneration (AMD)
|
|
JP2005511713A
(ja)
*
|
2001-12-07 |
2005-04-28 |
ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア |
加齢性黄斑変性についての処置
|
|
US6930085B2
(en)
*
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
BR0310100A
(pt)
*
|
2002-05-17 |
2007-04-27 |
Esperion Therapeutics Inc |
métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
|
|
AU2003239489A1
(en)
*
|
2002-05-17 |
2003-12-02 |
Esperion Therapeutics, Inc. |
Method of treating dyslipidemic disorders
|
|
NL1020962C2
(nl)
*
|
2002-06-28 |
2003-12-30 |
Tno |
Therapie en prognose/monitoring bij sepsis en septische shock.
|
|
MXPA05000050A
(es)
*
|
2002-07-03 |
2005-04-08 |
Esperion Therapeutics Inc |
Composiciones farmaceuticas y metodos para tratar, prevenir y manejar el colesterol, dislipidemia y enfermedades relacionadas.
|
|
US20040220190A1
(en)
*
|
2002-07-29 |
2004-11-04 |
Cincotta Anthony H. |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
|
US9655865B2
(en)
|
2002-07-29 |
2017-05-23 |
Veroscience, Llc |
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
|
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
|
US20040081678A1
(en)
*
|
2002-08-09 |
2004-04-29 |
Anthony Cincotta |
Therapeutic process for the treatment of obesity and associated metabolic disorders
|
|
US8821915B2
(en)
|
2002-08-09 |
2014-09-02 |
Veroscience, Llc |
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
|
|
CA2503284A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Enos Pharmaceuticals, Inc. |
Sustained release l-arginine formulations and methods of manufacture and use
|
|
HUE036646T2
(hu)
*
|
2003-01-23 |
2018-07-30 |
Esperion Therapeutics Inc |
Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
|
|
DK1641421T3
(en)
|
2003-07-03 |
2019-03-11 |
Hdl Therapeutics Inc |
Methods and apparatus for producing HDL particle derivatives of reduced lipid content
|
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
WO2005058938A2
(en)
*
|
2003-12-15 |
2005-06-30 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
US7959659B2
(en)
*
|
2004-01-02 |
2011-06-14 |
Advanced Cardiovascular Systems, Inc. |
High-density lipoprotein coated medical devices
|
|
US8137993B2
(en)
*
|
2004-03-25 |
2012-03-20 |
Veroscience Llc |
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
|
|
US8137994B2
(en)
*
|
2004-03-25 |
2012-03-20 |
Veroscience Llc |
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
|
|
US20050215558A1
(en)
*
|
2004-03-25 |
2005-09-29 |
Cincotta Anthony H |
Methods of identifying responders to dopamine agonist therapy
|
|
JP2007531537A
(ja)
*
|
2004-04-06 |
2007-11-08 |
セダーズ−シナイ メディカル センター |
アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
|
|
EP1602931A1
(en)
*
|
2004-06-03 |
2005-12-07 |
Universiteit Leiden |
SR-A antagonists
|
|
MXJL06000069A
(es)
*
|
2004-06-09 |
2007-04-10 |
Avanir Pharmaceuticals |
Derivados heterociclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas.
|
|
EP1753782A1
(en)
*
|
2004-06-09 |
2007-02-21 |
Avanir Pharmaceuticals |
Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
|
|
RU2006146479A
(ru)
*
|
2004-06-09 |
2008-07-20 |
Аванир Фармасьютикалс (Us) |
Небольшие молекулярные медиаторы для лечения гиперхолестеринемии и связанных заболеваний
|
|
EP2309269B1
(en)
|
2004-09-08 |
2016-10-26 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Compositions and methods for the detection of HIV-1/HIV-2 infection.
|
|
US20060205669A1
(en)
*
|
2004-09-16 |
2006-09-14 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
|
ATE469174T1
(de)
|
2004-10-15 |
2010-06-15 |
Us Gov Health & Human Serv |
Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
|
|
WO2006063132A2
(en)
|
2004-12-06 |
2006-06-15 |
The Regents Of The University Of California |
Methods for improving the structure and function of arterioles
|
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
KR20080007491A
(ko)
*
|
2005-04-29 |
2008-01-21 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
|
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US20060275356A1
(en)
*
|
2005-05-25 |
2006-12-07 |
Burgess James W |
Pharmaceutical compositions for treating or preventing coronary artery disease
|
|
GR1005428B
(el)
*
|
2005-05-27 |
2007-02-01 |
Χαραλαμπος Αλεξοπουλος |
Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah)
|
|
JP5113752B2
(ja)
|
2005-08-22 |
2013-01-09 |
メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド |
Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
|
|
GB0602598D0
(en)
*
|
2006-02-09 |
2006-03-22 |
Cheesmond David |
Quick change front F2 sidecar
|
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
|
TW200744627A
(en)
*
|
2006-02-21 |
2007-12-16 |
Pfizer Prod Inc |
Methods for the treatment of macular degeneration and related eye conditions
|
|
CA2653840A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Institut De Cardiologie De Montreal |
Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
|
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
EP2041174A2
(en)
*
|
2006-06-16 |
2009-04-01 |
Lipid Sciences, Inc. |
Novel peptides that promote lipid efflux
|
|
WO2008021088A2
(en)
*
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
WO2008039843A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Lipid Sciences, Inc. |
Novel peptides that promote lipid efflux
|
|
CA3021932C
(en)
*
|
2007-01-31 |
2020-12-15 |
Jds Therapeutics, Llc |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
|
CA2678813A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Melior Pharmaceuticals I, Inc. |
Methods of identifying activators of lyn kinase
|
|
DK2465519T3
(da)
|
2007-03-01 |
2014-02-03 |
Csl Ltd |
Behandling af endotel funktionsforstyrrelse hos diabetespatienter
|
|
ES2841379T3
(es)
|
2007-03-13 |
2021-07-08 |
Jds Therapeutics Llc |
Procedimientos y composiciones para la liberación sostenida de cromo
|
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
|
CA2693809A1
(en)
*
|
2007-07-23 |
2009-01-29 |
Melior Discovery, Inc. |
Methods of activating irs-1 and akt
|
|
US8431529B2
(en)
*
|
2007-07-31 |
2013-04-30 |
Sanford-Burnham Medical Research Institute |
Bi-dentate compounds as kinase inhibitors
|
|
CA2695384A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Burnham Institute For Medical Research |
Bi-dentate compounds as kinase inhibitors
|
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
CN101842101A
(zh)
*
|
2007-08-29 |
2010-09-22 |
加利福尼亚大学董事会 |
水杨酰苯胺修饰的肽用作口服治疗剂
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US9173890B2
(en)
*
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
*
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8044021B2
(en)
*
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
WO2009129263A1
(en)
*
|
2008-04-15 |
2009-10-22 |
The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. |
Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
|
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
CA2788223A1
(en)
|
2009-01-23 |
2010-07-29 |
Institut De Cardiologie De Montreal |
Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
LT2939683T
(lt)
*
|
2009-02-16 |
2017-03-27 |
Cerenis Therapeutics Holding Sa |
Apolipoproteino a-i mimetikai
|
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
|
US8980546B2
(en)
|
2009-05-21 |
2015-03-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for the detection of HIV-1-specific antibodies utilizing a Vpu polypeptide
|
|
US9352025B2
(en)
|
2009-06-05 |
2016-05-31 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
|
|
MX342785B
(es)
|
2009-06-10 |
2016-10-12 |
Alnylam Pharmaceuticals Inc |
Formulacion mejorada de lipido.
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
WO2011040654A1
(ko)
*
|
2009-09-30 |
2011-04-07 |
서울대학교산학협력단 |
아포리포프로테인 에이１ 모방 펩타이드，및 이를 포함하는 고지혈증 및 이와 관련된 질환 치료제
|
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
US10525152B2
(en)
|
2009-10-09 |
2020-01-07 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
US12419839B2
(en)
|
2009-10-09 |
2025-09-23 |
Signablok, Inc. |
Methods and compositions for targeted delivery of protein fragments
|
|
WO2011071860A2
(en)
|
2009-12-07 |
2011-06-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions for nucleic acid delivery
|
|
CA2784568A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Lipid particles for delivery of nucleic acids
|
|
US20110152112A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Artery Therapeutics, Inc. |
Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US20130137628A1
(en)
|
2010-05-11 |
2013-05-30 |
Esperion Therapeutics, Inc. |
Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
|
|
US20130158055A1
(en)
|
2010-05-28 |
2013-06-20 |
Andrew G. Reaume |
Prevention Of Pancreatic Beta Cell Degeneration
|
|
SG186085A1
(en)
|
2010-06-03 |
2013-01-30 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
US9339513B2
(en)
|
2010-11-09 |
2016-05-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
WO2012092365A1
(en)
|
2010-12-31 |
2012-07-05 |
Alphacore Pharma Llc |
Detection of lcat activity
|
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
EP2673296B1
(en)
|
2011-02-07 |
2018-10-24 |
Cerenis Therapeutics Holding SA |
Lipoprotein complexes and manufacturing and uses thereof
|
|
AU2012223282B2
(en)
|
2011-03-01 |
2017-02-02 |
Nutrition 21, Llc |
Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
|
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
AU2012346755B2
(en)
*
|
2011-11-30 |
2016-09-15 |
Daewoong Pharmaceutical Co., Ltd. |
Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases
|
|
EP2790704B1
(en)
|
2011-12-12 |
2019-04-03 |
Melior Pharmaceuticals I, Inc. |
Treatment of type i diabetes
|
|
US10017551B2
(en)
|
2013-03-15 |
2018-07-10 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
|
EP2853259A1
(en)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Reconstituted high density lipoproteins composition and uses thereof
|
|
WO2015173633A2
(en)
|
2014-05-02 |
2015-11-19 |
Cerenis Therapeutics Holding Sa |
Hdl therapy markers
|
|
WO2016011049A2
(en)
|
2014-07-14 |
2016-01-21 |
Schwendeman Anna |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
|
MX383117B
(es)
|
2014-07-31 |
2025-03-13 |
Anji Pharmaceuticals Inc |
Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
|
|
RU2022102472A
(ru)
|
2015-03-13 |
2022-03-15 |
Эсперион Терапеутикс, Инк. |
Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
|
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
|
WO2016154542A2
(en)
*
|
2015-03-25 |
2016-09-29 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cardiovascular related disorders
|
|
WO2016154544A1
(en)
*
|
2015-03-25 |
2016-09-29 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
AU2016291597B2
(en)
|
2015-07-10 |
2021-01-14 |
Peptinovo Biopharma, Llc |
Formulations for improving the efficacy of hydrophobic drugs
|
|
CA3014308A1
(en)
|
2016-02-11 |
2017-08-17 |
Nutrition 21, Llc |
Chromium containing compositions for improving health and fitness
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
EP3490579B1
(en)
|
2016-07-27 |
2025-09-10 |
Hartis-Pharma SA |
Therapeutic combinations to treat red blood cell disorders
|
|
FR3061715B1
(fr)
|
2017-01-12 |
2021-07-30 |
Institut National Univ Jean Francois Champollion |
Peptide immunomodulateur
|
|
US11027052B2
(en)
|
2017-11-22 |
2021-06-08 |
HDL Therapuetics, Inc. |
Systems and methods for priming fluid circuits of a plasma processing system
|
|
SG11201909406VA
(en)
|
2017-04-10 |
2019-11-28 |
Melior Pharmaceuticals I Inc |
Treatment of adipocytes
|
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
Cargomers
|
|
EP3687538B1
(en)
|
2017-10-30 |
2024-04-17 |
Montreal Heart Institute |
Methods of treating elevated plasma cholesterol
|
|
EP3731814A4
(en)
|
2017-12-28 |
2021-09-29 |
HDL Therapeutics, Inc. |
METHOD OF PRESERVATION AND ADMINISTRATION OF HIGH DENSITY PRE-BETA LIPOPROTEIN EXTRACTED FROM HUMAN PLASMA
|
|
CN110294791B
(zh)
*
|
2019-06-13 |
2023-02-21 |
倪京满 |
具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
|
|
CN112437766A
(zh)
|
2019-06-21 |
2021-03-02 |
艾斯柏伦治疗公司 |
制备贝派地酸及其组合物的方法
|
|
KR20230004605A
(ko)
|
2020-04-16 |
2023-01-06 |
아비오닉스 파마 에스에이 |
지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
|
|
MX2023003877A
(es)
|
2020-10-01 |
2023-04-18 |
Abionyx Pharma Sa |
Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
|
|
KR20240018430A
(ko)
|
2021-04-15 |
2024-02-13 |
아비오닉스 파마 에스에이 |
기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
|
|
CA3247588A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
|
|
AU2023250345A1
(en)
|
2022-04-06 |
2024-11-14 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
WO2023237927A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
|
|
JP2025519606A
(ja)
|
2022-06-10 |
2025-06-26 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
|
|
WO2024150064A1
(en)
|
2023-01-13 |
2024-07-18 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|
|
WO2025093929A1
(en)
|
2023-10-31 |
2025-05-08 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|